Literature DB >> 19201583

Chitosan-coated liposomes for delivery to lungs by nebulisation.

Marco Zaru1, Maria-Letizia Manca, Anna Maria Fadda, Sophia G Antimisiaris.   

Abstract

The preparation of Chitosan (CHT)-coated liposomes and their applicability as a carrier for delivery of drugs to the lungs by nebulisation was investigated. Empty SUV (small unilamellar) liposomes were initially prepared (with different lipid compositions) and coated with CHT by dropwise addition of CHT solution in the liposome dispersion. CHT-coating efficiency was calculated after separation of coated/non-coated liposomes by centrifugation, and measurement of lipid in each fraction. After establishing the best conditions for CHT-coating (concentration of CHT in the solution), RIF-loaded CHT-coated liposomes, with different lipid compositions (negatively charged and non-charged) were constructed, and their encapsulation efficiency (EE) and nebulisation efficiency (NE%)/stability (NER%) were evaluated. Charged liposomes (containing phosphatidylglycerol [PG]) can be coated with CHT better compared to non-charged ones. The EE of CHT-coated liposomes (that contain PG) is slightly increased while their stability after nebulisation is significantly increased (NER%). Mucoadhesive properties of CHT-coated liposomes were substantially better (compared to non-coated ones) while the toxicity of liposomal RIF towards A549 epithelial cells was lower compared to free drug for all the types of vesicles evaluated, and especially the CHT-coated ones. Thereby, it is concluded that CHT-coated liposomes have advantages (compared to non-coated) when the delivery of drugs to the lungs by nebulisation is considered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19201583     DOI: 10.1016/j.colsurfb.2009.01.010

Source DB:  PubMed          Journal:  Colloids Surf B Biointerfaces        ISSN: 0927-7765            Impact factor:   5.268


  13 in total

1.  Chitosan coating of copper nanoparticles reduces in vitro toxicity and increases inflammation in the lung.

Authors:  Kristan L S Worthington; Andrea Adamcakova-Dodd; Amaraporn Wongrakpanich; Imali A Mudunkotuwa; Kranti A Mapuskar; Vijaya B Joshi; C Allan Guymon; Douglas R Spitz; Vicki H Grassian; Peter S Thorne; Aliasger K Salem
Journal:  Nanotechnology       Date:  2013-09-05       Impact factor: 3.874

2.  PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination.

Authors:  Hardeep S Oberoi; Yvonne M Yorgensen; Audrey Morasse; Jay T Evans; David J Burkhart
Journal:  J Control Release       Date:  2015-11-06       Impact factor: 9.776

3.  Nebulized liposomal gadobenate dimeglumine contrast formulation for magnetic resonance imaging of larynx and trachea.

Authors:  Xiaohui Wei; Huawei Wu; Qing Lu; Jianrong Xu; Yuhong Xu
Journal:  Int J Nanomedicine       Date:  2011-12-19

4.  Novel drug delivery systems: desired feat for tuberculosis.

Authors:  Kirtipal Kaur; Anuj Gupta; R K Narang; R S R Murthy
Journal:  J Adv Pharm Technol Res       Date:  2010-04

5.  Chemical coupling of thiolated chitosan to preformed liposomes improves mucoadhesive properties.

Authors:  Kerstin Gradauer; Caroline Vonach; Gerd Leitinger; Dagmar Kolb; Eleonore Fröhlich; Eva Roblegg; Andreas Bernkop-Schnürch; Ruth Prassl
Journal:  Int J Nanomedicine       Date:  2012-05-21

6.  Chitosan in mucoadhesive drug delivery: focus on local vaginal therapy.

Authors:  Toril Andersen; Stefan Bleher; Gøril Eide Flaten; Ingunn Tho; Sofia Mattsson; Nataša Škalko-Basnet
Journal:  Mar Drugs       Date:  2015-01-07       Impact factor: 5.118

7.  Chitosan-Based Nanomedicine to Fight Genital Candida Infections: Chitosomes.

Authors:  Toril Andersen; Ekaterina Mishchenko; Gøril Eide Flaten; Johanna U Ericson Sollid; Sofia Mattsson; Ingunn Tho; Nataša Škalko-Basnet
Journal:  Mar Drugs       Date:  2017-03-04       Impact factor: 5.118

8.  Hydrophobically modified chitosan nanoliposomes for intestinal drug delivery.

Authors:  M Gulrez Zariwala; Harshada Bendre; Anatoliy Markiv; Sebastien Farnaud; Derek Renshaw; Kevin Mg Taylor; Satyanarayana Somavarapu
Journal:  Int J Nanomedicine       Date:  2018-09-27

Review 9.  Inhaled Biologicals for the Treatment of Cystic Fibrosis.

Authors:  Valentina Sala; Alessandra Murabito; Alessandra Ghigo
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2019

10.  Composition influence on pulmonary delivery of rifampicin liposomes.

Authors:  Maria Letizia Manca; Chiara Sinico; Anna Maria Maccioni; Octavio Diez; Anna Maria Fadda; Maria Manconi
Journal:  Pharmaceutics       Date:  2012-11-27       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.